The FDA green light for aducanumab for Alzheimer’s disease raised many red flags. Will it be approved here?
With the FDA approval of a disease-modifying drug for Alzheimer’s disease, manufacturer Biogen should be raking it in.
Instead, it is laying off hundreds of employees, having sold just $US300,000 worth of aducanumab (Aduhelm) in the quarter after its controversial approval.
Now that the monoclonal antibody is up for approval by the Therapeutic Goods Administration, The Tea Room spoke to neuroscientist Associate Professor Scott Ayton from the Florey Institute in Melbourne about why the drug has flopped in America, despite the desperate demand.
We discuss whether time is up for amyloid as the most promising drug target in Alzheimer’s research, and what other avenues should be investigated.
You can listen and subscribe to the show by searching for “The Tea Room Medical Republic” in your favourite podcast player.
